Eisai Co., Ltd. (“the Company”) and its affiliates (collectively referred to as “the Group”)
List of Group Companies(As of March 31, 2023)
Company Name

Location

Share Capital

Description ofOperations (*1)

VotingRights(*2)

Relationship

Note(Consolidated Subsidiaries)
Unit=million
KAN ResearchInstitute, Inc.

Kobe, Japan

70

JPY

Pharmaceutical R&D

100.00%Eisai R&D
Management Co.,Ltd.

Tokyo, Japan

16JPY

Management ofpharmaceutical R&D

100.00%Sunplanet Co., Ltd.

Tokyo, Japan

455

JPY

Business support
services, etc.

100.00%EA Pharma Co.,Ltd.

Tokyo, Japan

9,145

JPY

Pharmaceutical R&D/ production / sales

60.00%

Arteryex Inc.

Tokyo, Japan

434

JPY

Software planningand development

64.42%

Eisai Corporation ofNorth America

New Jersey,
USA

Americas holding
company

100.00%

The Company
commissions
pharmaceutical R&D
The Company
commissions a part ofmanagement and otherfunctions related to R&D
The Company purchases
business support services,etc.
The Company
commissions
pharmaceutical R&D andproduction / purchases
pharmaceutical products
The Company
commissions systemdevelopment*3

Unit=thousand

Eisai Inc.

New Jersey,
USA

Eisai Innovation,
Inc.

1,766,700

USD

The Company
commissions
pharmaceutical R&D andproduction / sells
pharmaceutical productsand APIThe Company
commissions managementof investment in the U.S.
and Europe

151,600

USD

Pharmaceutical R&D/ production / sales

100.00%(100.00%)

Massachusetts,USA1USD

Management ofpharmaceuticalinvestment

100.00%(100.00%)

Eisai Ltd.

Ontario, Canada

30,000CAD

Pharmaceutical sales

100.00%(100.00%)-

Eisai China
Holdings Ltd.

Jiangsu, China

664,465

RMB

Chineseheadquarters /holding company

100.00%(100.00%)-

Eisai China Inc.

Jiangsu, China

576,125

RMB

Pharmaceuticalproduction / sales

100.00%(100.00%)

Jiangsu, China

70,000

RMB

Pharmaceutical sales

100.00%(100.00%)

Liaoning, China

50,000

RMB

Pharmaceuticalproduction / sales

100.00%(100.00%)

100.00%Eisai (Suzhou)
Trading Co., Ltd.
Eisai (Liaoning)
PharmaceuticalCo., Ltd.
Eisai Europe Ltd.

Hertfordshire,UK

184,138

GBP

Europe headquarters/ holding company,
pharmaceutical sales

Eisai Ltd.

Hertfordshire,UK

46,009GBP

Pharmaceutical R&D/ sales100.00%(100.00%)

Eisai Manufacturing
Ltd.

Hertfordshire,UK

38,807

GBP

Pharmaceutical R&D/ production

100.00%(100.00%)

Eisai GmbH

Frankfurt,
Germany

7,669

EUR

Pharmaceutical sales

Eisai S.A.S.

Paris, France

19,500EURPharmaceutical sales

Eisai B.V.

Amsterdam,Netherlands

540

EUR

Pharmaceutical sales

Eisai Farmacéutica
S.A.

Madrid, Spain

4,000EUR

Pharmaceutical sales

100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)

The Company sells
pharmaceutical products
and APIThe Company sells
pharmaceutical products*3*3*5*7*3*3*3

The Company
commissions management
and administration ofpharmaceutical business
The Company
commissions
pharmaceutical R&D
The Company sells
pharmaceutical products
and API / is commissioned
pharmaceutical R&D-*3*3*3

Company Name

Location

Description ofOperations (*1)

Share Capital

VotingRights(*2)

Relationship

Note

Unit= thousand
Eisai S.r.l.
Eisai Pharma AG
Eisai AB
Eisai Farmacêutica,
Unipessoal Lda.
Eisai SA/NV

Milan, Italy
Zurich,Switzerland
Stockholm,
SwedenLisbon,Portugal
Brussels,
Belgium

3,500

EUR

Pharmaceutical sales

3,000

CHF

Pharmaceutical sales

10,000SEK

Pharmaceutical sales

1,250

EUR

Pharmaceutical sales

2,001

EUR

Pharmaceutical sales

100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)-Eisai GesmbH

Vienna, Austria

2,000

EUR

Pharmaceutical sales-Limited Liability
Company Eisai
Eisai Asia Regional
Services Pte. Ltd.
Eisai (Singapore)
Pte. Ltd.
Eisai ClinicalResearchSingapore Pte. Ltd.

Moscow,
Russia

4,000

RUB

Pharmaceutical sales

Singapore

34,469

SGD

Asia holding company

100.00%-Eisai Taiwan Inc.

The Company sells
pharmaceutical products
The Company
commissions
pharmaceutical R&D
The Company sells
pharmaceutical products
The Company sells
pharmaceutical products
The Company sells
pharmaceutical products
and APIThe Company sells
pharmaceutical products
The Company sells
pharmaceutical products
The Company sells
pharmaceutical products
The Company sells
pharmaceutical products
The Company
commissions
pharmaceutical R&D andproduction / sells
pharmaceutical products
and API / purchases
pharmaceutical products
and API-Singapore

300

SGD

Pharmaceutical sales

100.00%(100.00%)

Singapore

10SGD

Pharmaceutical R&D

100.00%(100.00%)

Taipei, Taiwan

270,000

TWD

Pharmaceutical sales

100.00%Eisai (Thailand)Marketing Co., Ltd.

Bangkok,Thailand

103,000

THB

Pharmaceutical sales

100.00%(100.00%)

PT Eisai Indonesia

Jakarta,Indonesia

1,630,000

IDR

Pharmaceuticalproduction / sales

100.00%470

MYR

Pharmaceutical sales

122,000

PHP

Pharmaceutical sales

Hong Kong

500

HKD

Pharmaceutical sales

Eisai Korea Inc.

Seoul,South Korea

3,512,000

KRW

Pharmaceutical sales

100.00%

Eisai
Pharmaceuticals
India Pvt. Ltd.

AndhraPradesh,India

2,708,324

INR

Pharmaceutical R&D /production / sales

100.00%(11.08%)Eisai Australia Pty.
Ltd.
Eisai Laboratórios
Ltda.
Eisai Laboratorios
S. de R.L. de C.V.
Eisai New ZealandLtd.
Eisai Vietnam Co.,Ltd.

Sydney,Australia
São Paulo,
BrazilMexico City,
MexicoAuckland,
New ZealandHo Chi Minh,
Viet Nam

4,000

AUD

Pharmaceutical sales

100.00%87,899BRL

Pharmaceutical sales

3MXN

Pharmaceutical sales

2,050

NZD

Pharmaceutical sales

20,781,000

VND

Pharmaceutical sales

100.00%-Eisai Israel Ltd.

Tel Aviv, Israel

5,000

ILS

Pharmaceutical sales

100.00%(100.00%)-Johannesburg,
South Africa

24,000ZAR

Pharmaceuticalbusiness

100.00%----

Provision of medical
services

49.00%(49.00%)-Eisai (Malaysia)
Sdn. Bhd.
HI-Eisai
Pharmaceutical Inc.
Eisai (Hong Kong)
Co., Ltd.

Eisai
Pharmaceuticals
Africa (Pty) Ltd
Other – 2
companies

Petaling Jaya,
Malaysia
Manila,Philippines---100.00%(5.74%)
50.00%(1.45%)
100.00%(10.00%)100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)-

Unit=million
Shanghai,
China

30

RMB

*3

-

(Associated Companies Accounted for Using the Equity Method)
Unlimit Health
Limited*4*6Notes:*1. "Description of Operations" indicates the segment applicable to the respective entity.
*2. Voting rights (%): Figures in parentheses show percentage indirectly owned by the Company.
*3. Significant subsidiaries.
*4. HI-Eisai Pharmaceutical Inc. is considered to be a consolidated subsidiary as the Company holds effective control
over its operation even though the Company's voting rights do not exceed 50%.
*5. Eisai Inc. is the only subsidiary whose revenue to external customers exceeds 10% of consolidated revenue reported
in the consolidated financial statements for the fiscal year ended March 31, 2023. Key financial results (in Japaneseyen) of Eisai Inc. are as follows:
Revenue
Operating Profit
Profit for the year
Total Equity
Total Assets
*6.
*7.
*8.
*9.

¥327,720 mil.
¥16,963 mil.
¥17,819 mil.
¥330,051 mil.
¥489,960 mil.

In May 2022, the Company established Eisai Pharmaceuticals Africa (Pty) Ltd.
In December 2022, H3 Biomedicine Inc. was integrated into Eisai Inc.
In March 2023, the Company transferred all shares (100.0% of the number of shares issued) of Eisai Distribution
Co., Ltd. to Yasuda Logistics Corporation (Tokyo).
In March 2023, the Company transferred all shares (49.0% of the number of shares issued) of Bracco-Eisai Co., Ltd.
to Bracco Imaging S.p.A. (Italy).